Johnson & Johnson (JNJ) has been a standout performer in the healthcare sector, and our analysis suggests there's more to come. With a strong pipeline, a robust dividend, and a clean slate post-separation, JNJ is poised for continued growth. Our price target of $278.53, based on a 90% confidence level, reflects a 8.39% upside from the current price. This article delves into the factors driving JNJ's success, the risks involved, and how it compares to peers like Merck and Pfizer. We also explore the potential for JNJ to reach $291 and beyond, considering catalysts like ICOTYDE and the growth trajectory of its Innovative Medicine brands. However, we also address the potential downsides, including the impact of biosimilars on STELARA and the execution risks associated with the Orthopaedics spin-off. Ultimately, our analysis concludes that JNJ's setup favors the bull case, with a 5-year base case reaching $353.01, representing a 37.37% total return.
